



Final Appraisal Recommendation

Advice No: 0413 – February 2013

Insulin glargine (Lantus®) 100 units/ml solution for injection

Limited submission by Sanofi

Recommendation of AWMSG

Insulin glargine (Lantus®) 100 units/ml solution for injection is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in children aged 2 to less than 6 years.

Additional note:

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Sanofi-Aventis Ltd
Date of first issue	February 2013
Last reviewed	September 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0413: insulin glargine (Lantus®) 100 units/ml solution for injection. February 2013



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.